Introduction
============

Asthma and chronic obstructive pulmonary disease(COPD) are prevalent chronic diseases in the community.^[@bib1]^ In the Netherlands, 60 to 80% of all asthma and COPD patients are treated by their general practitioner (GP), and patients are only referred to the pulmonologist in case of severe uncontrolled asthma or severe COPD.^[@bib2]^ Misdiagnosis and underdiagnosis are common,^[@bib3; @bib4; @bib5]^ as asthma and COPD overlap in symptoms, whereas their treatments are different.^[@bib6]^ Some patients have both asthma and COPD, the so-called overlap syndrome, which can be described as (partly) reversible but progressive deterioration in lung function, often combined with a history of smoking and previous diagnosis of asthma and/or allergies. These diagnostic problems may lead to suboptimal treatment, whereas early correct treatment can reduce costs, morbidity and mortality, can improve symptoms and enhance patient outcomes.^[@bib3; @bib4; @bib5],[@bib7]^

In daily clinical practice, many GPs often lack the knowledge, time and enthusiasm to perform all tasks that are recommended by guidelines. For example, Dutch GPs are obliged to follow 96 guidelines for common diseases, of which only three are concerned with asthma, asthma in children, and COPD.^[@bib8; @bib9; @bib10]^ GPs therefore could benefit from the knowledge and experience of pulmonologists by obtaining advice for each patient with pulmonary symptoms. Cooperation between GPs and other caregivers in integrated care projects for COPD patients has been proven to be effective in improving the quality of life and health status of patients, thus reducing costs and the number of hospitalisations.^[@bib11],[@bib12]^ Asthma/COPD services in which GPs are supported by pulmonologists in interpreting spirometry results are feasible and might improve diagnostic accuracy.^[@bib13]^ GPs and pulmonologists in the North of the Netherlands collaborated and implemented the Asthma/COPD (AC) service in 2007 as a support service for GPs. The aim of this service is to improve the management of asthma and COPD patients in primary care. Although the service was not developed for scientific reasons, data from included patients are available for research. This paper describes the development and feasibility of this service, the patient population and its effect on patient-related outcomes.

Materials and Methods
=====================

Design and feasibility
----------------------

Meetings with local physicians were organised, resulting in four starting principles: (1) the service should optimise diagnosis, treatment and management; (2) the GP is in lead; (3) the service should be easily accessible for patients and physicians; (4) allocation of tasks between primary and secondary care have to be defined clearly.^[@bib14]^ Yearly meetings are organised to inform physicians about current developments, discuss casuistry and enhance commitment.

### The role of the GP

GPs can refer individual patients (⩾8 years of age) who are suspected to have asthma, COPD, overlap syndrome or present with pulmonary symptoms of unknown origin further referred to as obstructive airway disease (OAD). The GP can also choose to refer all OAD patients in his/her practice on the basis of inhaled medication use and/or courses of prednisolone. When preferred by the GP, referral may also include follow-up assessments by the AC service. Finally, the GP decides what to do with the advice of the pulmonologist and is responsible for the disease management.

### Self-reported information by patients

Patients complete the 'Asthma Control Questionnaire (ACQ),' the 'Clinical COPD Questionnaire (CCQ)' and a medical history questionnaire assessing gender, age, age of onset, family history, symptoms, exacerbations (having used oral corticosteroids or antibiotics for lung problems), allergy and other stimuli-provoking symptoms, medication, occupation and smoking history as part of the regular assessment procedure.

The ACQ is used to measure asthma control and contains six questions (range 0--6), and the total score can be divided into 'controlled' (\<0.75), 'partially controlled' (0.75--1.50) and 'uncontrolled' (⩾1.50).^[@bib14]^ The CCQ is used to measure COPD health status, and it contains 10 questions. The total score (range 0--6) can be distributed between 'stable' (\<1), 'not entirely stable',^[@bib1],[@bib2]^ 'unstable'^[@bib2],[@bib3]^ and 'very unstable' (⩾3). This questionnaire contains three subdomains with four questions about functional status, four questions about symptoms and two questions about mental status.^[@bib14],[@bib15]^

### Assessment by the trained lung function technician

The assessments take place in local laboratories according to a strict protocol. The following measurements are taken:

Body mass index.Evaluation and, if needed, instruction of the inhalation technique according to the Dutch 'Inhalation Medication Instruction School' guidelines.Spirometry according to international guidelines.^[@bib16]^

All data, including the scores on the questionnaires, are inserted in an Electronic Diagnostic Support (EDS) system.

### The role of the pulmonologist

Pulmonologists are trained in using the service by following at least two training sessions. In this paper, we included pulmonologists who had assessed ⩾300 patients to avoid the influence of learning effects. Pulmonologists assess the quality of the spirometry, inspect all outcomes in the Electronic Diagnostic Support system and make a report (based on current international guidelines^[@bib2],[@bib17]^) with diagnosis, follow-up and treatment advice. Treatment advice can include lifestyle advice (e.g., dietician, smoking cessation or physical activity) or medication change. Pulmonologists were not provided with strict diagnostic rules. The GPs receive the report from the pulmonologist within 5 working days through the internet directly in their patient information system.

Statistical data analyses
-------------------------

IBM-SPSS version 22 was used for statistical analysis. The baseline population was described by age, gender, body mass index, exacerbation history, smoking history, lung function performances, diagnosis and GOLD 2013 category (A, B, C and D).^[@bib17]^ A positive bronchodilator response was defined as an increase in forced expiratory volume in 1 s (FEV~1~) of ⩾12% and ⩾200 ml. The median scores of GOLD A, B, C and D patients on the CCQ subscales are presented.

### Feasibility analyses

Feasibility was assessed by analysing the following: (1) the proportion of GPs in the target area who used the AC service between 2007 and 2012; (2) the proportion of patients with asthma or COPD who were assessed by the service in the target area since 2007;^[@bib18]^ (3) the quality of the spirometry; (4) the number of patients that could be diagnosed, and the variation in diagnostic pattern between the different pulmonologists by using chi-square.

### Follow-up visits

Patients for whom medication change was advised by the pulmonologist were automatically scheduled for an additional follow-up assessment after 3 months (range 2--4 months, *n*=740). If the GP requested follow-up visits and no medication change was advised, patients were assessed after 12 months (range 10--14, *n*=938). Baseline data of adult patients on exacerbations/year, smoking status, inhalation technique, ACQ and CCQ scores were compared with follow-up data. Nonparametric paired tests were used to compare baseline data with follow-up data. Paired *t*-tests were used for the longitudinal evaluation of FEV~1~(in litres). Follow-up data of baseline GOLD stages are presented to show the distribution of these patients to other GOLD stages.^[@bib17]^ To prevent overlap in our results, we excluded patients with \>1 follow-up assessment in 1 year (*n*=79).

Results
=======

Baseline patient characteristics are presented in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}.

Feasibility
-----------

The service included around 2,000 (range: 1,813--2,109) new patients yearly from 79.3% of the GPs in the target area. Approximately 50% of patients were included by practice screening. In all, 60% of all adult asthma and COPD patients in the target area were assessed at least once by the AC service.^[@bib18],[@bib19]^ Pulmonologists considered the quality of 93.6% of the spirometry graphs to be usable for diagnosis and could diagnose 79.4% of the patients (asthma: 45.8%, COPD: 17.8%, overlap syndrome: 6.9%). See [Supplementary 1](#xob1){ref-type="supplementary-material"} for an overview of COPD GOLD A, B, C and D patients at baseline. Baseline diagnosis was compared with follow-up diagnosis, and it did not change during the follow-up in 91.2% (confidence interval: 89.4--92.7%) of baseline asthma patients, in 87.7% (confidence interval: 84.4--90.4%) of baseline COPD patients and in 74.2% (confidence interval: 68.0--79.5%) of baseline overlap syndrome patients. There was variation in diagnostic pattern in adult patients between the different pulmonologists (*n*=10, *P*\<0.000); see [Figure 1](#fig1){ref-type="fig"}.

Follow-up visits
----------------

Patients frequently changed from GOLD (2013) category, and many GOLD D patients (*n*=74) moved to other GOLD categories at follow-up (Follow-up category: GOLD A: 21.6%, B: 36.5%, C: 6.8%, D: 35.1%); see [Figure 2](#fig2){ref-type="fig"}.

### Patients advised to change medication (Patients followed-up after 3 months, total=740)

Inhalation technique improved significantly (correct at baseline 35.1% to 52.5% after 3 months, *n* total=459, *P*\<0.000). The proportion of well-controlled asthma patients increased from 23.9% (baseline) to 49.5% (3 months, *n* total=487, *P*\<0.000), and the proportion of stable COPD patients increased from 27.4% (baseline) to 48.9% (3 months, *n* total=145, *P*=0.004). The proportion of GOLD D patients decreased from 12.8% at baseline to 6.7% after 3 months; see [Table 3](#tbl3){ref-type="table"} (*n* total=145, *P*\<0.000).

### Patients advised to continue current medication (Patients followed-up after 12 months, *n*=938)

Inhalation technique did improve significantly (correct baseline 37.4 to 49.9% after 12 months, *n*=741, *P*\<0.000). The proportion of current smokers decreased from 25.2% at baseline to 23.2% after 12 months (*n*=984, *P*=0.013). The proportion of asthma and COPD patients with ⩾1 exacerbation last year decreased (asthma: 35.0% at baseline, 25.2% at 12 months, *P*\>0.000; COPD: 34.8% at baseline, 25.4% at 12 months, *P*=0.010); see [Table 4](#tbl4){ref-type="table"}.

Discussion
==========

Main findings
-------------

In this study, we have evaluated over 11,000 patients referred by 360 different GPs to the Asthma/COPD (AC) service in the North of the Netherlands. With 60% of all asthma and COPD patients in the area participating, the service is well implemented in the target area. We chose to report the follow-up results from patients who were advised to change medication after 3 months separately from the patients who were advised to continue with their medication and were scheduled to have a 12-month follow-up. If a change in medication was advised, after 3 months, health status improved in COPD patients and asthma control improved in asthma patients. Asthma and COPD patients who did not need medication change and were referred to the yearly follow-up assessment stabilised in asthma control and in COPD health status. Overlap syndrome patients in this group improved in asthma control and health status. Most (65%) of the GOLD D patients moved to other categories after baseline visit; some of these patients (22%) even improved to GOLD category A. Given these results, we consider the AC service to be a feasible and effective collaboration service for primary and secondary care.

Interpretation of findings in relation to previously published work
-------------------------------------------------------------------

According to the Global Initiative for Asthma guidelines, uncontrolled asthma patients would be eligible for referral to secondary care.^[@bib2]^ The prevalence of uncontrolled asthma patients in our population (age ⩾16 years) is lower (40%) than the prevalence found in the INSPIRE study where 51% of the patients had uncontrolled asthma.^[@bib20]^ Only 13% of our asthma patients were advised to be referred to secondary care (see [Table 1](#tbl1){ref-type="table"}), meaning that the pulmonologists did not follow the Global Initiative for Asthma guidelines. However, we do not know whether the GP followed the referral recommendation of the pulmonologist.

The accuracy of the diagnosis in Asthma/COPD support systems is of pivotal importance. Lucas *et al.* showed previously that a diagnosis based on paper patient data without life contact in an AC service is comparable with diagnoses acquired by a face-to-face consultation. The level of agreement on diagnoses between paper data and face-to-face diagnoses was κ=0.82,^[@bib21]^ which exceeded the level of inter-doctor agreement from the different assessing pulmonologists (κ=0.64^[@bib22]^). We used comparable history questions and spirometry as Lucas *et al.* used, and we assume that the diagnostic accuracy will be comparable as in the study of Lucas *et al.* Diagnoses during follow-up visits in our AC service (see [Figure 1](#fig1){ref-type="fig"}) showed that most of the diagnoses were consistent. Although diagnoses are to some extent subjective, the advantage of the system is that the GP can compare his own choices with the diagnoses and advices from the pulmonologist. We believe that this internet-based consultation in the long run might improve skills in the management of OADs.

Van den Bemt *et al.* ^[@bib23]^ presented a service for COPD patients and concluded that it was not clinically effective. However, their population consisted of already-diagnosed COPD patients, and all patients had performed spirometry previously to inclusion, whereas we followed up both previously diagnosed and newly diagnosed patients. We speculate that the room for improvement in our population of a wide range of patients was higher, which might have contributed to the positive effect. Furthermore, internet is used for data exchange, and GPs receive the report from the pulmonologist mostly within 5 working days electronically in their patient information system, which makes the service user friendly. Next to that, the use of Internet and the trained lung function technicians make the service cost-effective. Direct costs were covered by reimbursement for the spirometry in primary care, including the involvement of the pulmonologist.

### Generalisability

Our asthma patients differed from COPD patients, whereas the characteristics of overlap syndrome patients fell between asthma and COPD patients. This was also described by Postma *et al.* ^[@bib24]^ who showed that asthma patients are younger, more frequently female and have less frequently a history of smoking. Miravitlles *et al.* ^[@bib25]^ showed the same pattern of patient characteristics in their primary care population, although the proportion of male patients in their overlap syndrome population was much lower than in the AC population (Miravitlles: 26%, AC service: 49%). Characteristics of our asthma patients (⩾16 years) were comparable with asthmatics from the INSPIRE study (AC service: male, 38%; mean age, 46±17 years; current smokers, 21%. INSPIRE: male 35%; mean age, 45±17 years; current smokers, 21%).

When considering overlap syndrome as a subtype of COPD, the prevalence of overlap syndrome in our COPD population was 28%, which is comparable to the prevalence found by Ställberg *et al.*[@bib26] (25%) but higher than the prevalence reported by Postma *et al.* (13--20%).^[@bib24]^ Our overlap patients have more frequent exacerbations compared with the asthma and COPD patients, which indicate that these patients are more at risk for future exacerbations. This high risk was confirmed in other studies.^[@bib24],[@bib27],[@bib28]^ Although these patients are more at risk, at baseline only the CCQ scores reflect this poor health status (CCQ⩾3: COPD, 8%; overlap syndrome, 10%). Overlap patients were assessed by using the ACQ and the CCQ, because these questionnaires were part of the regular assessment in the AC collaboration service. However, no validated measurements are available to assess the health status and disease control in overlap patients. COPD patients in the AC service were distributed according to the GOLD guidelines using CCQ cutoff value of \>1 (A: 28%, B: 40%, C: 8% and D: 24%). Lange *et al.* ^[@bib29]^ distributed 6,628 Danish COPD patients using the modified Medical Research Council and found another distribution (A: 77%, B: 14%, C: 4% and D: 4%). Apart from the difference in symptom assessment by using the CCQ instead of the modified Medical Research Council, our COPD sample of primary care--treated patients is obviously more at risk and has more symptoms than the Danish general population.

### Reversibility

Only 17% of our asthma patients had a positive bronchodilator test (BDT) response.^[@bib2]^ In asthma patients with good lung function (FEV~1~/forced vital capacity (FVC) after bronchodilator ⩾90%), the proportion of patients with a positive BDT was 5%, whereas in asthma patients with very poor lung function (FEV~1~/FVC post bronchodilator \<70%), this proportion was 40%. Others have also shown that reversibility in asthmatic patients depends on the severity of asthma as measured by the impairment in lung function.^[@bib30]^ Although COPD is considered to be a nonreversible obstructive lung disease, 11% of our COPD patients had a BDT response, and the average reversibility was 6%. In the UPLIFT study, 50% of the COPD patients showed significant reversibility.^[@bib31]^ Obviously, real-life COPD populations differ from selected populations, as confirmed by Kruis *et al.* ^[@bib32]^ Bronchodilator response was more prevalent in COPD patients with severe disease.^[@bib24]^The highest proportion of patients with positive BDT response was seen in the overlap syndrome patients (35%), which is consistent with the GOLD and Global Initiative for Asthma recommendations.^[@bib33]^

### Risk factors

The proportion of smoking COPD and overlap syndrome patients (COPD: 50%, overlap syndrome: 45%) was much higher than in the Dutch population, which is 27%, and also higher than the COPD population presented by Warnier *et al.*^[@bib34]^ (37%). Our definition of smokers might have contributed to the higher proportion, because we considered quitters \<12 months ago as current smokers. The AC service does not provide any cessation intervention but informs the GP if their patients are motivated to quit. The follow-up time of 12 months could not reveal the number of quitters (\>12 months) as a result of the possible intervention of the GP.

Like in other studies,^[@bib35]^ many patients (64%) showed an insufficient inhalation technique. Although the inhalation technique improved after 3 (50%) and 12 months (47%) of follow-up after our standard instruction as recommended in the Dutch guidelines, it is debatable whether this instruction is sufficiently effective. Further research on effective instruction seems to be needed.

Strengths and limitations of this study
---------------------------------------

The strength of this study is the large population of primary care OAD patients in real life and the strict protocol used to assess these patients. A limitation is that the AC service was not established for scientific reasons, resulting in limited follow-up results, and data could not be compared with a control group.^[@bib36]^ Therefore, we cannot rule out that results might have been affected by regression to the mean, although regression to the mean (measured by 1−*ρ*) is small;^[@bib37]^ see [Supplementary 2](#xob1){ref-type="supplementary-material"}. We also do not have data on mortality; however, on the basis of national mortality data, we assume that 1.8% of the COPD patients have died in 1 year. Leivseth *et al.* ^[@bib38]^ showed that there are no large differences in mortality rates between GOLD A, B, C and D. Therefore, we assume that missed mortality rates hardly affected our COPD follow-up results.

Implications for future research, policy and practice
-----------------------------------------------------

Relatively simple support for GPs in diagnosing and managing patients with a chronic disease by specialists might result in improved outcomes for these patients in the community. Principles of the AC service might also be suitable in other chronic diseases. The large electronic database from the AC service provides unique opportunities for further research in primary care patients with OADs.

Conclusion
----------

The AC service is feasible, effective and efficient in supporting GPs to diagnose and manage asthma, COPD and overlap syndrome patients. The service stimulates cooperation between primary and secondary care, and delivers support to patients locally which is important in rural areas.
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![This picture shows the variation in diagnoses in adult patients between the assessing pulmonologists. Most variation is seen in the diagnoses of asthma and other (unclear diagnoses, indication for restriction or no disease). The variation in diagnoses between the pulmonologists was significant (Chi-square=580, *n*=10,656, *P*\<0.000).](npjpcrm2014101-f1){#fig1}

![Distribution of COPD patients at baseline (*n* (total)=2,004) according to the new GOLD classification of airflow limitation. Apparent is the large proportion of patients at risk: 22% of the COPD patients were classified as GOLD D. GOLD D patients have a high risk of exacerbations combined with a high burden of disease.](npjpcrm2014101-f2){#fig2}

###### Baseline characteristics of the total patient population in the AC tele-medicine service

  *Variable*                                *Total group,* n*=11,401*
  ---------------------------------------- ---------------------------
  *Diagnosis of*                                     *n* (%)
   COPD                                           2,031 (17.8)
    Very unstable (CCQ⩾3)                           161 (8.0)
   Asthma                                         5,223 (45.8)
    Uncontrolled (ACQ⩾1.50)                       2,049 (39.3)
   Asthma/COPD overlap syndrome                     787 (6.9)
    Very unstable (CCQ⩾3)                           77 (9.9)
    Uncontrolled (ACQ⩾1.50)                        308 (39.4)
  Indication for restriction                        159 (1.4)
  No lung disease                                   796 (7.0)
  Unclear diagnosis                               2,354 (20.6)
  Missing at random                                 15 (0.1)
                                           
  *Diagnosis is unclear because of*                  *n* (%)
   Incorrect lung function test                    297 (12.6)
   Unknown                                        2,057 (87.4)
                                           
  *Referral to pulmonologist because of*             *n* (%)
   Unclear diagnosis                              1,966 (54.7)
   Indication of restriction                       18 (0.005)
   Unable to perform lung function test            18 (0.005)
   COPD                                            558 (15.5)
    FEV~1~ \<50% predicted                         302 (54.3)
   Asthma/COPD overlap syndrome                     214 (6.0)
    FEV~1~ \<50% predicted                          27 (12.7)
   Asthma                                          690 (19.2)
    Unstable (ACQ⩾1.50)                            469 (68.2)
   Total                                          3,593 (31.5)
                                           
  *Quality lung function test*                       *n* (%)
   Sufficient                                     10,670 (93.6)
   Insufficient                                     730 (6.4)

In 31.5% of the assessments, the pulmonologist advised the GP to refer their patient to secondary care mostly because of unclear diagnosis (54.7%). Most patients with unclear diagnosis (age, 51±19; age of onset, 39±23; 42% male) had no obstruction (FEV~1~/FVC⩾70%: 90%), no positive bronchodilator response (93%) and no allergy (76%). However, these patients were high in symptoms (CCQ⩾1: 68%).

Abbreviations: AC, asthma/COPD; ACQ, Asthma Control Questionnaire; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity; GP, general practitioner.

###### Baseline characteristics of the patient population per diagnosis

  *Variable*                                                      *COPD,* n*=2,031*   *Overlap syndrome,* n*=787*            *Asthma,* n*=5,223*
  -------------------------------------------------------------- ------------------- ----------------------------- ---------------------------------------
  *Gender and age*                                                     *n* (%)                  *n* (%)                            *n* (%)
   Male                                                             1,190 (58.6)              388 (49.3)                        2,007 (38.4)
   Self-reported ⩾1 allergy                                          243 (12.0)               312 (39.6)                        2,658 (50.9)
                                                                                                                   
                                                                     Mean (s.d.)              Mean (s.d.)                        Mean (s.d.)
   Age, years                                                        66.6 (10.8)              60.6 (12.3)                        43.6 (18.7)
   Age of onset, years                                               52.2 (19.6)              33.6 (23.1)                        22.3 (19.6)
   Body mass index (kg/m^2^)                                         26.6 (4.8)               27.1 (4.9)                         26.7 (6.0)
   Exacerbations in the last 12 months                                0.7 (1.1)                0.9 (1.2)                          0.8 (1.2)
                                                                                                                   
  *Lung function post bronchodilator, mean (s.d.)*                                                                 
   FEV~1~ (L)                                                         2.0 (0.7)                2.3 (0.7)                          3.1 (0.9)
   FEV~1~% predicted                                                 69.0 (18.1)              76.0 (15.5)                        94.6 (15.1)
   FVC (L)                                                            3.6 (1.0)                3.7 (1.1)                          4.0 (1.1)
   FVC % predicted                                                   98.6 (18.4)             102.1 (17.2)                       101.1 (16.3)
   FEV~1~/FVC                                                        56.0 (11.2)              61.0 (9.5)                         79.3 (8.8)
   Reversibility[a](#t2-fn1){ref-type="fn"}                           6.4 (7.9)               11.2 (10.0)                         6.7 (7.6)
                                                                                                                   
  *Positive BDT* [b](#t2-fn2){ref-type="fn"} *adults,* n *(%)*                                                     
   Post FEV~1~/FVC\<70%                                              198 (99.0)               236 (91.5)            204 (25.0)[c](#t2-fn3){ref-type="fn"}
   Post FEV~1~/FVC=70--80%                                             2 (1.0)                 22 (8.5)                          358 (43.8)
   Post FEV~1~/FVC=80--90%                                                                                                        214(26.2)
   Post FEV~1~/FVC⩾90%                                                                                                            40 (4.9)
   Total                                                             200 (10.7)               258 (34.8)                         817 (16.6)
                                                                                                                                       
  *Inhalation technique* [a](#t2-fn1){ref-type="fn"}, n *(%)*                                                      
   Correct                                                           325 (36.1)               205 (36.5)                        1,434 (38.0)
   Incorrect                                                         576 (63.9)               357 (63.5)                        2,339 (62.0)
                                                                                                                   
  *Smoking history (age⩾18 years),* n *(%)*                                                                        
   Smoking history missing                                             8 (0.4)                  0 (0.0)                           17 (0.4)
   Never smoked                                                       70 (3.4)                 54 (6.9)                         2,041 (43.4)
   Quit ⩾12 months ago                                               948 (46.7)               378 (48.0)                        1,628 (34.6)
   Current smoker                                                   1,005 (49.5)              355 (45.1)                        1,014 (21.6)
    Males                                                            517 (51.4)               151 (42.5)                         383 (37.8)
    Males motivated to quit                                          304 (58.8)                89 (58.9)                         231 (60.3)
    Females                                                          475 (47.3)               197 (55.5)                         614 (60.6)
    Females motivated to quit                                        295 (62.1)               112 (56.8)                         407 (66.3)

Abbreviations: BDT, bronchodilator test; COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity.

Increase in FEV~1~ pre bronchodilator compared with FEV~1~ post bronchodilator.

Positive bronchodilator response test defined as a reversible lung function of ⩾200 ml and ⩾12% increase in FEV~1~ pre bronchodilator compared with FEV~1~ post bronchodilator.

Adult asthma patients (male: 59%, mean age: 52 years, 19% current smokers) with obstruction before and after bronchodilator.

###### Longitudinal differences in lung function, exacerbations, health status and asthma control of patients assessed at baseline and after 3 months (range: 2--4 months, *n* total=740)

  *Diagnosis*                                                     n    *Baseline*    *After 3 months*   P *value* [a](#t3-fn1){ref-type="fn"}
  ------------------------------------------------------------- ----- ------------- ------------------ ---------------------------------------
  *Asthma (*n*=503)*                                                     *n* (%)         *n* (%)       
   ⩾1 exacerbation last year[b](#t3-fn2){ref-type="fn"}          483   188 (38.9)                      
   Current smoker                                                497    92 (18.5)       87 (17.5)                        NS
   Sufficient inhalation technique[c](#t3-fn3){ref-type="fn"}    320   120 (37.5)       173 (54.1)                     \<0.000
   Well controlled (ACQ\<0.75)                                   497   119 (23.9)       246 (49.5)                     \<0.000
   Partially controlled (ACQ⩾0.75 and \<1.50)                          174 (35.0)       136 (27.4)     
   Uncontrolled (ACQ⩾1.50)                                             204 (41.0)       115 (23.1)     
                                                                       Mean (s.d.)     Mean (s.d.)     
   FEV~1\ pre~ (L)                                               455    3.0 (0.9)       2.9 (0.9)                      \<0.000
                                                                                                       
  *COPD (*n*=148)*                                                       *n* (%)         *n* (%)       
   ⩾1 exacerbation                                               148    60 (40.5)                      
   Current smoker or quit \<12 months ago                        147    63 (42.9)       62 (42.2)                        NS
   Sufficient inhalation technique[c](#t3-fn3){ref-type="fn"}    79     19 (24.1)       38 (48.1)                        NS
   Stable (CCQ\<1)                                               147    55 (37.4)       75 (51.0)                       0.004
   Not entirely stable (CCQ⩾1 &\<2)                                     64 (43.5)       48 (32.7)      
   Unstable (CCQ⩾2 and \<3)                                             19 (12.9)       18 (12.2)      
   Very unstable (CCQ⩾3)                                                 9 (6.1)         6 (4.1)       
                                                                       Mean (s.d.)     Mean (s.d.)     
   FEV~1\ pre~ (L)                                               148    2.1 (0.6)       2.1 (0.6)                        NS
                                                                                                       
  *Overlap syndrome (*n*=82)*                                            *n* (%)         *n* (%)       
   ⩾1 exacerbation                                               82     41 (50.0)                      
   Current smoker or quit \<12 months ago                        82     33 (40.2)       34 (41.5)                        NS
   Sufficient inhalation technique[c](#t3-fn3){ref-type="fn"}    58     21 (36.2)       29 (50.0)                        NS
   Well controlled (ACQ\<0.75)                                   82     35 (42.7)       48 (58.5)                        NS
   Partially controlled (ACQ⩾0.75 and \<1.50)                           30 (36.6)       19 (23.2)      
   Uncontrolled (ACQ⩾1.50)                                              17 (20.7)       15 (18.3)      
   Stable (CCQ\<1)                                               31     8 (25.8)        16 (51.6)                       0.073
   Not entirely stable (CCQ⩾1 &\<2)                                     16 (51.6)       11 (35.5)      
   Unstable (CCQ⩾2 and \<3)                                             7 (22.6)         2 (6.5)       
   Very unstable (CCQ⩾3)                                                 0 (0.0)         2 (6.5)       
                                                                       Mean (s.d.)     Mean (s.d.)     
   FEV~1\ pre~ (L)                                               81     2.3 (0.6)       2.3 (0.7)                        NS

Patients were referred to the 3-month follow-up assessment if change in medication was advised by the pulmonologist.

Abbreviations: ACQ, Asthma Control Questionnaire; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second; NS, not significant.

*P* values are two-sided and *P* values ⩾0.10 are reported as 'NS'.

Exacerbations are defined as having used oral corticosteroids or antibiotics for lung problems last year.

Inhalation technique in patients who use medication at baseline.

###### Longitudinal differences in lung function, exacerbations, health status and asthma control of patients referred by their GP to single or yearly follow-up assessment after 12 months (range 10--14 months, *n* total=991). Patients in this table were not assessed after 3 months

  *Diagnosis*                                                     n    *Baseline*    *After 12 months*   P *value* [a](#t4-fn1){ref-type="fn"}
  ------------------------------------------------------------- ----- ------------- ------------------- ---------------------------------------
  *Asthma (*n*=598)*                                                     *n* (%)          *n* (%)       
   ⩾1 exacerbation[b](#t4-fn2){ref-type="fn"}                    572   200 (35.0)       144 (25.2)                      \<0.000
   Current smokers or quit \<12 months ago                       595    88 (14.8)        81 (13.6)                        NS
   Sufficient inhalation technique[c](#t4-fn3){ref-type="fn"}    471   185 (39.3)       251 (53.3)                      \<0.000
   Well controlled (ACQ\<0.75)                                   591   377 (63.8)       383 (64.8)                        NS
   Partially controlled (ACQ⩾0.75 and \<1.50)                          119 (20.1)       123 (20.8)      
   Uncontrolled (ACQ⩾1.50)                                              95 (16.1)        85 (14.4)      
                                                                       Mean (s.d.)      Mean (s.d.)     
   FEV~1\ pre~ (L)                                               596    3.1 (0.9)        3.0 (0.9)                      \<0.000
                                                                                                        
  *COPD (*n*=245)*                                                       *n* (%)          *n* (%)       
   ⩾1 exacerbation[b](#t4-fn2){ref-type="fn"}                    244    85 (34.8)        62 (25.4)                       0.010
   Current smokers or quit \<12 months ago                       243   109 (44.9)        99 (40.7)                       0.017
   Sufficient inhalation technique[c](#t4-fn3){ref-type="fn"}    177    59 (33.3)        78 (44.1)                       0.034
   Stable (CCQ\<1)                                               243   128 (52.7)       136 (56.0)                        NS
   Not entirely stable (CCQ⩾1 and \<2)                                  79 (32.5)        74 (30.5)      
   Unstable (CCQ⩾2 &\<3)                                                23 (9.5)         24 (9.9)       
   Very unstable (CCQ⩾3)                                                13 (5.3)          9 (3.7)       
                                                                       Mean (s.d.)      Mean (s.d.)     
   FEV~1\ pre~ (L)                                               244    2.2 (0.7)        2.1 (0.6)                      \<0.000
                                                                                                        
  *Overlap syndrome (*n*=88)*                                            *n* (%)          *n* (%)       
   ⩾1 exacerbation[b](#t4-fn2){ref-type="fn"}                    88     34 (38.6)        25 (28.4)                        NS
   Current smokers or quit \<12 months ago                       88     38 (43.2)        34 (38.6)                       0.094
   Sufficient inhalation technique[c](#t4-fn3){ref-type="fn"}    66     24 (36.4)        28 (42.4)                        NS
   Well controlled (ACQ\<0.75)                                   87     37 (42.5)        48 (55.2)                       0.032
   Partially controlled (ACQ⩾0.75 and \<1.50)                           25 (28.7)        21 (24.1)      
   Uncontrolled (ACQ⩾1.50)                                              25 (28.7)        18 (20.7)      
   Stable (CCQ\<1)                                               65     24 (36.9)        30 (46.2)                       0.027
   Not entirely stable (CCQ ⩾1 & \<2)                                   27 (41.5)        26 (40.0)      
   Unstable (CCQ⩾2 and \<3)                                             7 (10.8)         7 (10.8)       
   Very unstable (CCQ⩾3)                                                7 (10.8)          2 (3.1)       
                                                                       Mean (s.d.)      Mean (s.d.)     
   FEV~1\ pre~ (L)                                               88     2.3 (0.7)        2.2 (0.7)                      \<0.000

Abbreviations: ACQ, Asthma Control Questionnaire; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second; GP, general practitioner; NS, not significant.

*P* values are two-sided and *P* values ⩾0.10 are reported as 'ns'.

Exacerbations are defined as having used oral corticosteroids or antibiotics for lung problems last year.

Inhalation technique in patients who use medication at baseline.

[^1]: All authors have contributed to writing and revising the manuscript.
